RWJ 29009

Drug Profile

RWJ 29009

Latest Information Update: 12 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johnson & Johnson
  • Class Antihypertensives; Ischaemic heart disorder therapies; Peripheral vasodilators; Small molecules
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypertension; Myocardial ischaemia

Most Recent Events

  • 19 Aug 1997 Suspended-Preclinical for Hypertension in USA (Unknown route)
  • 19 Aug 1997 Suspended-Preclinical for Myocardial ischaemia in USA (Unknown route)
  • 26 Jun 1995 Investigation in Hypertension in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top